Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström's Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.
Dana-Farber/Brigham and Women's Cancer Center.
Kenneth C
KC
Anderson
Melissa
M
Alsina
William
W
Bensinger
J Sybil
JS
Biermann
Adam D
AD
Cohen
Steven
S
Devine
Benjamin
B
Djulbegovic
Edward A
EA
Faber
Christine
C
Gasparetto
Francisco
F
Hernandez-Ilizaliturri
Carol Ann
CA
Huff
Adetola
A
Kassim
Amrita Y
AY
Krishnan
Bruno C
BC
Medeiros
Ruby
R
Meredith
Noopur
N
Raje
Jeffrey
J
Schriber
Seema
S
Singhal
George
G
Somlo
Keith
K
Stockerl-Goldstein
Steven P
SP
Treon
Guido
G
Tricot
Donna M
DM
Weber
Joachim
J
Yahalom
Furhan
F
Yunus
Rashmi
R
Kumar
Dorothy A
DA
Shead
D000465:Algorithms; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D008495:Medical Oncology / Q000639:trends*; D020360:Neoadjuvant Therapy; D010523:Peripheral Nervous System Diseases / Q000276:immunology / Q000628:therapy; D011379:Prognosis; D012008:Recurrence; D000069283:Rituximab; D016879:Salvage Therapy; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000628:therapy*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D000069283:Rituximab